News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
536,215 Results
Type
Article (37772)
Company Profile (184)
Press Release (498259)
Section
Business (164752)
Career Advice (2185)
Deals (28643)
Drug Delivery (101)
Drug Development (68688)
Employer Resources (139)
FDA (13204)
Job Trends (12542)
News (280356)
Policy (26037)
Tag
Academia (2129)
Alliances (39211)
Alzheimer's disease (1057)
Approvals (13124)
Artificial intelligence (102)
Bankruptcy (235)
Best Places to Work (9583)
Biosimilars (70)
Biotechnology (98)
Breast cancer (84)
Cancer (710)
Career advice (1827)
Cell therapy (144)
Clinical research (54727)
Collaboration (241)
Compensation (131)
COVID-19 (2209)
Data (611)
Diabetes (113)
Diagnostics (5076)
Drug pricing (90)
Earnings (68438)
Employer resources (125)
Events (78649)
Executive appointments (203)
FDA (13507)
Funding (206)
Gene therapy (126)
GLP-1 (568)
Government (3542)
Healthcare (14615)
Infectious disease (2267)
Inflammatory bowel disease (86)
Interviews (389)
IPO (12975)
Job creations (3197)
Job search strategy (1559)
Layoffs (369)
Legal (5779)
Lung cancer (132)
Manufacturing (135)
Medical device (9237)
Medtech (9242)
Mergers & acquisitions (15700)
Metabolic disorders (352)
Neuroscience (1260)
NextGen Class of 2024 (5129)
Non-profit (3459)
Northern California (898)
Obesity (217)
Opinion (215)
Patents (80)
People (45260)
Pharmaceutical (78)
Phase I (16967)
Phase II (23735)
Phase III (18634)
Pipeline (175)
Policy (69)
Postmarket research (2087)
Preclinical (6374)
Radiopharmaceuticals (212)
Rare diseases (147)
Real estate (4642)
Regulatory (17702)
Research institute (1915)
Resumes & cover letters (344)
Southern California (783)
Startups (3014)
United States (8354)
Vaccines (480)
Weight loss (190)
Date
Today (139)
Last 7 days (481)
Last 30 days (2203)
Last 365 days (29813)
2024 (24081)
2023 (32766)
2022 (42450)
2021 (45460)
2020 (43809)
2019 (37785)
2018 (28877)
2017 (27392)
2016 (26462)
2015 (30314)
2014 (23654)
2013 (19699)
2012 (21161)
2011 (21764)
2010 (19566)
Location
Africa (744)
Arizona (99)
Asia (33974)
Australia (5296)
California (1955)
Canada (930)
China (155)
Colorado (92)
Connecticut (87)
Europe (73856)
Florida (293)
Illinois (231)
Indiana (151)
Kansas (86)
Maryland (318)
Massachusetts (1563)
Michigan (96)
Minnesota (171)
New Jersey (628)
New York (572)
North Carolina (536)
Northern California (898)
Ohio (94)
Pennsylvania (538)
South America (1003)
Southern California (783)
Texas (272)
Washington State (238)
536,215 Results for "ea pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist, Signed between EA Pharma and Ensho Therapeutics
EA Pharma Co., Ltd. and Ensho Therapeutics, Inc. announced that the two companies have signed a worldwide exclusive license agreement for the rights to develop, manufacture and commercialize novel oral inflammatory bowel disease treatments EA1080 and a portfolio of other oral selective α4β7 integrin antagonists for the global market excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEAN.
June 27, 2024
·
5 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Drug Development
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
Ensho Therapeutics, Inc. launched with the announcement that it has acquired a portfolio of oral α4β7 integrin inhibitors through a worldwide exclusive license agreement with EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd.
June 27, 2024
·
9 min read
Layoffs
Athira Pharma to Lay Off 70% of Workforce
Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s disappointing results for its investigational Alzheimer’s therapy.
September 23, 2024
·
1 min read
·
Angela Gabriel
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
·
1 min read
·
Angela Gabriel
Mergers & acquisitions
Broken Deals: 4 Pharma Assets Returned to Biotech This Year
Not all licensing deals are successful. Here,
BioSpace
examines a few noteworthy assets that Big Pharma returned in the last 12 months.
August 27, 2024
·
5 min read
·
Mollie Barnes
Drug Development
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
June 6, 2024
·
6 min read
Cell and gene therapy
Big Pharma’s Interest Grows in Evolving Cell and Gene Therapy Sector
Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.
October 9, 2024
·
4 min read
·
Greg Slabodkin
Pharm Country
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a positive Type C meeting with the U.S. Food and Drug Administration (“FDA”). Eagle and the FDA agreed on a path forward to advance the clinical development of EA-114, an estrogen receptor antagonist used in the treatment of breast cancer in post-menopausal women.
August 29, 2023
·
8 min read
Approvals
ARS Pharma Gets FDA Green Light for First Nasal Spray for Severe Allergic Reactions
ARS Pharma’s neffy on Friday became the first FDA-approved nasal spray to address severe allergic reactions, including those that might lead to life-threatening anaphylaxis.
August 12, 2024
·
2 min read
·
Tristan Manalac
1 of 53,622
Next